Reading Room Production — page 440

tiuse and uum that can commercially usable drugs, the tension between broad use leading to resistance development, vs.. preserving for resistance and MCM needs. Of interest, perhaps somewhat in between, and in some cases more realistic than truly broad spectrum, are interventions that may be dual or multi-use but not truly "broad spectrum" , such as an antibiotic that might be active both against terrorism threats and against specific resistant organisms in the health care setting. Or a radiation injury treatment that might be useful in cancer therapy, marrow transplantation and in radiation injury. I know this is what is intended by all of us but wanted to emphasize for discussions. One way to discuss for non-medical audiences might be that beyond a single only emergency use, dual use, multiuse and broad spectrum agents and platforms can be part of a more technologically advanced and strategic continuum that can increase economic incentives, US competitiveness, preparedness and health benefits. Thanks Jesse From: Korch, George (HHS/ASPR/IO) [mailto: @hhs.gov] Sent: Tuesday, January 19, 2010 4:31 PM To: Frieden, Thomas (CDC); Commissioner FDA; Fauci, Anthony S (NIH); Goodman, Jesse Cc: Sosin, Daniel M. (CDC); Kurilla, Michael G (NIH); Robinson, Robin (OS); Khabbaz, Rima F. (CDC); Parker, Gerald (OS) Subject: Sustainable systems for PHEMCE products (v8 0 NL)RM jl edits.doc Drs Frieden, Hamburg, Fauci and Goodman: Attached, please find the final version of the paper on the PHEMCE enterprise for discussion this evening with Ms. Heidi Avery and the NSS. Dr. Lurie has also asked that I have available the more fully developed texts that you all provided earlier to further inform the White House staff. V/r, George George W. Korch, Jr. Senior Science Advisor ASPR